A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection

详细信息    查看全文

• 作者：Xin Wang ; Yali Shen ; Hong Zhu ; Yaqin Zhao ; Zhiping Li ; Meng Qiu ; Qiu Li…
• 关键词：Gastric cancer ; D2 lymph node dissection ; Adjuvant chemoradiotherapy ; 3D ; CRT ; IMRT
• 刊名：Gastric Cancer
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：19
• 期：1
• 页码：245-254
• 全文大小：553 KB
• 参考文献：1.Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.PubMed PubMedCentral
  2.Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633–49.PubMed CrossRef
  3.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMed CrossRef
  4.Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63:1279–85.PubMed CrossRef
  5.Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.PubMed CrossRef
  6.Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMed CrossRef
  7.Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37.PubMed CrossRef
  8.Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMed CrossRef
  9.Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33.PubMed PubMedCentral CrossRef
  10.Milano MT, Garofalo MC, Chmura SJ, Farrey K, Rash C, Heimann R, et al. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol. 2006;79:497–503.PubMed CrossRef
  11.Ringash J, Perkins G, Brierley J, Lockwood G, Islam M, Catton P, et al. IMRT for adjuvant radiation in gastric cancer: a preferred plan? Int J Radiat Oncol Biol Phys. 2005;63:732–8.PubMed CrossRef
  12.Cividalli A, Ceciarelli F, Livdi E, Altavista P, Cruciani G, Marchetti P, et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys. 2002;52:1092–8.PubMed CrossRef
  13.Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncology. 2002;20:2844–50.CrossRef
  14.Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005;10:49–58.PubMed CrossRef
  15.Zhang XL, Shi HJ, Cui SZ, Tang YQ, Ba MC. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol. 2011;37:466–72.PubMed CrossRef
  16.Catalano V, Bisonni R, Graziano F, Giordani P, Alessandroni P, Baldelli AM. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer. 2013;16:411–9.PubMed CrossRef
  17.Wang X, Wang Y, Qiu M, Li Q, Li ZP, He B, et al. Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen). Med Oncol. 2011;28(Suppl 1):S274–9.PubMed CrossRef
  18.Matzinger OGE, Bernstein Z, Maingon P, Haustermans K, Bosset JF, Gulyban A, et al. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol. 2009;92:164–75.PubMed CrossRef
  19.National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). http://​ctep.​cancergov/​forms/​CTCAEv3.​pdf . Accessed on 15 July 2005.
  20.Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulate rate compared with constant rate. J Natl Cancer Inst. 1990;82:1046–50.PubMed CrossRef
  21.Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III–IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012;84:e585–92.PubMed CrossRef
  22.Zhu WG, Xua DF, Pu J, Zong CD, Li T, Tao GZ, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104:361–6.PubMed CrossRef
  23.Lee J, do Lim H, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73.PubMed CrossRef
  24.Wieland P, Dobler B, Mai S, Hermann B, Tiefenbacher U, Steil V, et al. IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys. 2004;59:1236–44.PubMed CrossRef
  25.Leong T, Willis D, Joon DL, Condron S, Hui A, Ngan SY. 3D conformal radiotherapy for gastric cancer—results of a comparative planning study. Radiother Oncol. 2005;74:301–6.PubMed CrossRef
  26.Soyfer V, Corn BW, Melamud A, Alani S, Tempelhof H, Agai R, et al. Three-dimensional non-coplanar conformal radiotherapy yields better results than traditional beam arrangements for adjuvant treatment of gastric cancer. Int J Radiat Oncol Biol Phys. 2007;69:364–9.PubMed CrossRef
  27.El-Hossiny HA, Diab NA, El-Taher MM. A comparative dosimetric study of adjuvant 3D conformal radiotherapy for operable stomach cancer versus AP-PA conventional radiotherapy in NCI-Cairo. J Egypt Natl Cancer Inst. 2009;21:197–202.
  28.Minn AY, Hsu A, La T, Fisher GA, Ford JM, Norton JA, et al. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer. 2010;116:3943–52.PubMed CrossRef
  29.Quero L, Bouchbika Z, Kouto H, Baruch-Hennequin V, Gornet JM, Munoz N, et al. Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer. Int J Radiat Oncol Biol Phys. 2012;83:574–80.PubMed CrossRef
  30.Leong T, Joon DL, Willis D, Jayamoham J, Spry N, Harvey J, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2011;79:690–5.PubMed CrossRef
  31.Boda-Heggemann J, Weiss C, Schneider V, Hofheinz RD, Haneder S, Michaely H, et al. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol. 2013;189:417–23.PubMed CrossRef
  32.Hofheinz RD, Wenz F, Lukan N, Mai S, Kripp M, Staiger W, et al. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer—an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys. 2009;73:142–7.PubMed CrossRef
  33.Orditura M, De Vita F, Muto P, Vitiello F, Murino P, Lieto E, et al. Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg. 2010;145:233–8.PubMed CrossRef
  34.Osti MF, Agolli L, Bracci S, Monaco F, Tubin S, Minniti G, et al. Adjuvant chemoradiation with 5-fluorouracil or capecitabine in patients with gastric cancer after D2 nodal dissection. Anticancer Res. 2012;32:1397–402.PubMed
  35.Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, et al. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol. 2012;104:367–73.PubMed CrossRef
  36.Kilic L, Ordu C, Ekenel M, Yildiz I, Keskin S, Sen F, et al. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients? Med Oncol. 2013;30:660.PubMed CrossRef
  
• 作者单位：Xin Wang (1) (2)
  Yali Shen (1) (2)
  Hong Zhu (1)
  Yaqin Zhao (1)
  Zhiping Li (1)
  Meng Qiu (1)
  Qiu Li (1)
  Hongfeng Gou (1)
  Yu Yang (1)
  Dan Cao (1)
  Jiyan Liu (1)
  Cheng Yi (1)
  Zhengyin Liao (1)
  Deyun Luo (1)
  Feng Bi (1)
  Feng Xu (1)
  
  1. Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 of Wainan Guoxue Lane, Wuhou District, Chengdu, 610041, Sichuan Province, People’s Republic of China
  2. State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Gastroenterology
  Surgical Oncology
  Pathology
  Radiotherapy
  
• 出版者：Springer Japan
• ISSN：1436-3305

文摘

Background To evaluate the safety and efficacy of a concurrent three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) plus oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) regimen in completely resected gastric cancer patients with D2 lymph node dissection.